ift-43 Antibody

What is IFT-43 and what is its functional significance in cellular biology?

IFT43 (Intraflagellar Transport 43 Homolog) is a protein that functions as a subunit of the intraflagellar transport complex A (IFT-A). This complex plays a crucial role in cilia assembly and maintenance by mediating retrograde ciliary transport along microtubules from the ciliary tip to the base . The IFT-A complex is specifically required for the entry of G protein-coupled receptors (GPCRs) into cilia, making it essential for ciliogenesis . IFT43 is primarily localized in the cytoplasm, cytoskeleton, and cell projections, with particular association with microtubules and concentration at the distal tip of the cilium . Mutations in the IFT43 gene are associated with cranioectodermal dysplasia-3 (CED3), also known as Sensenbrenner syndrome, highlighting its physiological significance .

What types of IFT-43 antibodies are commercially available for research applications?

Several types of IFT-43 antibodies are available for research applications, with most being rabbit polyclonal antibodies that target different amino acid regions of the human IFT43 protein. These include unconjugated antibodies and various conjugated versions such as Cy5-conjugated , RBITC-conjugated , Biotin-conjugated, and antibodies conjugated to fluorescent dyes like AbBy Fluor® 350, 555, 594, 680, and 750 . The most common formats specifically target amino acid regions 111-208 or 145-171 of the human IFT43 protein . These antibodies are typically purified using Protein A and are formulated in storage buffers containing glycerol, BSA, and preservatives to maintain stability .

What are the primary applications for IFT-43 antibodies in research?

IFT-43 antibodies are utilized in multiple research applications with varying recommended dilution ranges. The primary applications include:

• Western Blotting (WB): Used to detect and quantify IFT43 protein expression, with recommended dilution ranges of 1:300-5000 or 1:500-2000 depending on the specific antibody

• Immunofluorescence on cultured cells (IF/ICC): For visualizing IFT43 localization within cells, typically at dilutions of 1:50-200

• Immunohistochemistry on paraffin-embedded (IHC-P) or frozen sections (IHC-F): For detecting IFT43 in tissue samples, at dilutions of 1:50-200

• ELISA: For quantitative detection of IFT43 in solution

• FACS (Flow Cytometry): For analyzing IFT43 expression in cell populations

Most antibodies demonstrate reactivity with human samples, with predicted cross-reactivity with mouse, rat, dog, cow, sheep, pig, and horse specimens based on sequence homology .

What is the recommended storage and handling protocol for IFT-43 antibodies?

To maintain optimal activity of IFT-43 antibodies, proper storage and handling are essential. Most IFT-43 antibodies should be stored at -20°C for up to one year from the date of receipt . The antibodies are typically supplied in aqueous buffered solutions containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300, and 50% glycerol or in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide . To prevent protein degradation and maintain antibody efficiency, it is crucial to avoid repeated freeze-thaw cycles by aliquoting the antibody into multiple small volumes before freezing . When using the antibody, it should be thawed completely and gently mixed before use. Proper handling practices will ensure consistent results and maximize the shelf-life of the antibody.

How can researchers optimize IFT-43 antibody specificity in co-localization studies with ciliary markers?

When designing co-localization studies to examine IFT43's position within ciliary structures, researchers should employ several optimization strategies. First, select an IFT-43 antibody with a fluorophore conjugate (such as Cy5 or RBITC ) that has minimal spectral overlap with other markers to reduce bleed-through during imaging. For optimal visualization, use antibodies targeting the 111-208 amino acid region of IFT43, as this encompasses the functionally relevant domain for IFT-A complex formation .

Implement a sequential immunostaining protocol, starting with the primary antibody requiring the most stringent conditions. When co-staining with basal body markers (e.g., γ-tubulin) or axonemal markers (e.g., acetylated α-tubulin), adjust the dilution of the IFT43 antibody to 1:100-1:150 for immunofluorescence applications to achieve balanced signal intensity . Consider signal amplification techniques for visualization of IFT43 at the distal tip of the cilium, where the protein is known to be concentrated . For confirming antibody specificity, include appropriate controls including IFT43 knockdown/knockout samples and pre-absorption tests with the immunizing peptide to validate the observed staining patterns.

What approaches are recommended for troubleshooting inconsistent Western blot results with IFT-43 antibodies?

When experiencing inconsistent Western blot results with IFT-43 antibodies, a systematic troubleshooting approach is necessary. First, optimize protein extraction by using specialized lysis buffers containing protease inhibitors that effectively solubilize membrane-associated and cytoskeletal proteins, as IFT43 associates with microtubules . The recommended protein amount for loading should be between 20-50μg per lane, with optimal antibody dilutions beginning at 1:500 and titrating as needed up to 1:2000 .

For enhanced detection of low abundance IFT43, implement extended transfer times (overnight at 30V) to ensure complete transfer of the protein from gel to membrane. When inconsistent results persist, consider the following: 1) validate sample integrity by probing for housekeeping proteins; 2) optimize blocking conditions using 5% BSA instead of milk to reduce background; 3) extend primary antibody incubation to overnight at 4°C; and 4) validate results using multiple IFT-43 antibodies targeting different epitopes . For samples with potentially low IFT43 expression, consider using unconjugated primary antibodies followed by highly sensitive detection systems rather than directly conjugated antibodies .

How can researchers effectively validate IFT-43 antibody specificity for new model organisms not listed in predicted reactivity?

When extending IFT-43 antibody use to new model organisms not listed in the predicted reactivity, a comprehensive validation approach is essential. Begin with an in silico analysis comparing the IFT43 amino acid sequence of your target organism with human IFT43, particularly focusing on the epitope region (e.g., AA 111-208) . Sequence homology above 80% suggests potential cross-reactivity. For experimental validation, implement a multi-method approach:

• Perform Western blotting with positive controls (human or mouse samples) alongside your target organism's samples, looking for bands at the expected molecular weight

• Include IFT43 knockdown/knockout samples from your model organism as negative controls

• Verify specificity through immunoprecipitation followed by mass spectrometry analysis to confirm target identity

• Conduct immunofluorescence co-localization with known ciliary markers to verify expected localization patterns

• Test multiple IFT-43 antibodies that target different epitopes to confirm consistent localization patterns

When publishing results in new model organisms, include detailed validation data and specify the exact antibody catalog number (e.g., ABIN1704959, bs-15562R-RBITC, or STJA0007126) to enable reproducibility in the research community.

What methodological approaches should be considered when studying the interaction between IFT-43 and other IFT-A complex components?

Studying interactions between IFT-43 and other IFT-A complex components requires sophisticated methodological approaches. Begin with co-immunoprecipitation (Co-IP) experiments using anti-IFT43 antibodies (preferably unconjugated versions) to pull down the entire IFT-A complex, followed by Western blotting for other complex components (IFT122, IFT140, IFT144). For detecting transient or weak interactions, consider implementing in situ proximity ligation assays (PLA) using IFT-43 antibodies in combination with antibodies against other IFT-A subunits.

For dynamic interaction studies, employ live-cell imaging using fluorescently tagged IFT43 antibody fragments (such as Cy5-conjugated versions) combined with photobleaching techniques (FRAP or FLIP) to measure association/dissociation kinetics. When mapping specific interaction domains, use a panel of IFT-43 antibodies targeting different epitopes (e.g., AA 111-208 vs. AA 145-171) in competition assays to identify regions critical for complex formation. For quantitative binding analysis, surface plasmon resonance (SPR) or biolayer interferometry (BLI) with purified components can be employed, using antibodies for detection or capture. These approaches should be complemented with functional assays that assess ciliary transport efficiency to correlate biochemical interactions with biological function.

How can researchers effectively detect and quantify IFT-43 in ciliopathy disease models or patient samples?

For detecting and quantifying IFT-43 in ciliopathy disease models or patient samples, researchers should implement a multi-modal approach that accommodates limited sample availability and potentially altered protein expression. Begin with immunohistochemistry on paraffin-embedded tissue sections (IHC-P) using IFT-43 antibodies at 1:50-100 dilutions to assess tissue distribution patterns, comparing control tissues with diseased samples. For quantitative analysis, employ automated image analysis software to measure signal intensity and ciliary localization patterns.

When working with patient-derived cell lines or tissue samples with potential IFT43 mutations, use Western blotting with antibodies targeting epitopes outside the mutation site to detect truncated or modified proteins. For precise quantification, implement droplet digital PCR (ddPCR) combined with proximity extension assays using IFT-43 antibodies for protein quantification. In cases where sample material is extremely limited, consider single-cell approaches using highly sensitive detection methods such as tyramide signal amplification (TSA) with IFT-43 antibodies. Always include appropriate controls including known ciliopathy samples with IFT-A defects and validated reference standards to enable cross-study comparisons and ensure reproducible quantification across different experimental batches.

What emerging research applications might benefit from advanced IFT-43 antibody technologies?

Emerging research applications that could benefit from advanced IFT-43 antibody technologies include single-molecule localization microscopy (SMLM) studies using photoactivatable fluorophore-conjugated antibodies to map precise IFT-43 distribution within ciliary subcompartments. Additionally, antibody-based proximity labeling techniques (such as APEX-conjugated IFT-43 antibodies) could identify novel interacting partners within the ciliary transport system. For therapeutic development, emerging antibody-drug conjugate technologies could potentially target defective ciliary transport in certain ciliopathies.